BR112016026575A2 - Mirna Expression Signature in Thyroid Tumor Classification - Google Patents

Mirna Expression Signature in Thyroid Tumor Classification

Info

Publication number
BR112016026575A2
BR112016026575A2 BR112016026575A BR112016026575A BR112016026575A2 BR 112016026575 A2 BR112016026575 A2 BR 112016026575A2 BR 112016026575 A BR112016026575 A BR 112016026575A BR 112016026575 A BR112016026575 A BR 112016026575A BR 112016026575 A2 BR112016026575 A2 BR 112016026575A2
Authority
BR
Brazil
Prior art keywords
tumor classification
thyroid tumor
expression signature
mirna expression
signature
Prior art date
Application number
BR112016026575A
Other languages
Portuguese (pt)
Inventor
Meiri Eti
Lithwick Yanai Gila
Benjamin Hila
Spector Yael
Barnett-Itzhaki Zohar
Original Assignee
Rosetta Genomics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rosetta Genomics Ltd filed Critical Rosetta Genomics Ltd
Publication of BR112016026575A2 publication Critical patent/BR112016026575A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

a presente invenção fornece um método para classificação de tumores da tireoide através da análise dos padrões de expressão de micrornas específicos em amostras de aspiração com agulha fina. a classificação de tumor da tireoide de acordo com uma assinatura de expressão de microrna permite a otimização do diagnóstico e do tratamento, assim como a determinação de uma terapia específica para a assinatura.The present invention provides a method for classifying thyroid tumors by analyzing specific microorn expression patterns in fine needle aspiration samples. Thyroid tumor classification according to a microrna expression signature allows optimization of diagnosis and treatment, as well as the determination of a specific therapy for the signature.

BR112016026575A 2014-05-13 2015-05-13 Mirna Expression Signature in Thyroid Tumor Classification BR112016026575A2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461992531P 2014-05-13 2014-05-13
US201461992756P 2014-05-13 2014-05-13
US201462069353P 2014-10-28 2014-10-28
US201562139066P 2015-03-27 2015-03-27
PCT/US2015/030564 WO2015175660A1 (en) 2014-05-13 2015-05-13 Mirna expression signature in the classification of thyroid tumors

Publications (1)

Publication Number Publication Date
BR112016026575A2 true BR112016026575A2 (en) 2017-12-12

Family

ID=54480610

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016026575A BR112016026575A2 (en) 2014-05-13 2015-05-13 Mirna Expression Signature in Thyroid Tumor Classification

Country Status (7)

Country Link
EP (1) EP3143162A4 (en)
JP (1) JP6216470B2 (en)
CN (1) CN106460053A (en)
BR (1) BR112016026575A2 (en)
CA (1) CA2945531C (en)
IL (1) IL248639A0 (en)
WO (1) WO2015175660A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106434872A (en) * 2016-08-11 2017-02-22 河南大学 MiRNA molecule marker hsa-miR-152-3p for diagnosing type 2 diabetes, and application thereof
CN107385093A (en) * 2017-09-07 2017-11-24 青岛大学 Primer composition and its application and application its product and product application method
CN107723365B (en) * 2017-09-11 2019-10-01 朱伟 One kind blood plasma miRNA marker relevant to lung squamous cancer auxiliary diagnosis and its application
CN108038352B (en) * 2017-12-15 2021-09-14 西安电子科技大学 Method for mining whole genome key genes by combining differential analysis and association rules
CA3088939A1 (en) * 2018-01-05 2019-07-11 Visiongate, Inc. Morphometric genotyping of cells using optical tomography for detecting tumor mutational burden
BR102018003587A2 (en) * 2018-02-23 2020-07-07 Onkos Diagnósticos Moleculares Ltda Me method and kit for detecting thyroid tumor type
CN108721318B (en) * 2018-05-16 2021-06-25 广东药科大学 Application of miR-125b and chemotherapeutic agent in preparation of medicine for treating thyroid cancer
JP7378739B2 (en) * 2018-08-10 2023-11-14 東レ株式会社 Kits, devices and methods for the detection of prostate cancer
CN109700824A (en) * 2019-01-08 2019-05-03 上海长海医院 Application of the miR-31 and the like in the drug of preparation prevention or treatment blood vessel endothelium injury
CN110499367B (en) * 2019-08-09 2022-11-22 深圳市第二人民医院 Biomarkers and uses thereof
CN113025714B (en) * 2021-03-23 2022-05-24 华中科技大学同济医学院附属同济医院 miRNA biomarker for papillary thyroid carcinoma lateral cervical lymph node metastasis diagnosis and detection kit
CN116769922B (en) * 2023-08-24 2023-11-24 四川大学华西医院 Application of reagent for detecting circulating sEV RNA, kit and diagnostic system

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011154008A1 (en) * 2010-06-11 2011-12-15 Rigshospitalet Microrna classification of thyroid follicular neoplasia
JP2014511677A (en) * 2011-03-22 2014-05-19 コーネル・ユニバーシティー Distinguishing benign and malignant thyroid lesions that are difficult to distinguish
EP2771487A1 (en) * 2011-10-27 2014-09-03 Asuragen, INC. Mirnas as diagnostic biomarkers to distinguish benign from malignant thyroid tumors

Also Published As

Publication number Publication date
JP2017521051A (en) 2017-08-03
IL248639A0 (en) 2017-01-31
WO2015175660A1 (en) 2015-11-19
CA2945531A1 (en) 2015-11-19
EP3143162A4 (en) 2017-04-26
CA2945531C (en) 2018-01-30
EP3143162A1 (en) 2017-03-22
CN106460053A (en) 2017-02-22
JP6216470B2 (en) 2017-10-18

Similar Documents

Publication Publication Date Title
BR112016026575A2 (en) Mirna Expression Signature in Thyroid Tumor Classification
NZ741324A (en) Anti-cd47 antibodies and methods of use
BR112018005164A2 (en) antibodies, nucleic acid, host cell, method for producing an antibody, pharmaceutical formulation, use of the antibody and method of treating an individual who has cancer
BR112016005816A2 (en) COMBINATION OF ANTI-LAG-3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES TO TREAT TUMORS
BR112017012621A2 (en) cyclic peptides with enhanced nerve binding selectivity, nanoparticles bound with said cyclic peptides, and their use for real time in vivo nerve tissue imaging
BR112016001611A2 (en) MULTI-SPECIFIC ANTIBODIES, MULTI-SPECIFIC ACTIVABABLE ANTIBODIES AND METHODS OF THEIR USE
MX2016002051A (en) Methods and kits for the molecular subtyping of tumors.
TR201812261T4 (en) CANCER TREATMENT WITH PI3 KINASE ISOFORM MODULATORS
BR112016027222A2 (en) isolated antibodies, isolated nucleic acid, host cell, method of producing an antibody, immunoconjugate, pharmaceutical formulation, methods of treating an individual with cancer, inhibiting cell proliferation, detecting human gpc3 and detecting a cancer
BR112017021312A2 (en) Lung cancer treatment with glutaminase inhibitors
BR112019001398A2 (en) Methods for Prostate Cancer Treatment
BR112017000714A2 (en) functionalized and substituted indols as anti-cancer agents
BR112016023607A2 (en) medical use of artemisinin compounds and gephyrin agonists
BR112015032758A2 (en) docetaxel polymeric nanoparticles for cancer treatment
UY34812A (en) METHOD FOR TREATMENT OF LUNG CANCER OF NON-SMALL CELLS
BR112016030172A2 (en) specific aptamers for tlr-4 and their uses
BR112016011734A2 (en) INDOLES SUBSTITUTED AND FUNCTIONALIZED AS ANTI-CANCER AGENTS
TR201909951T4 (en) A method for predicting the outcome of aflibercept treatment of a patient suspected of having cancer.
EP4249608A3 (en) Early lung cancer detection by dna methylation phenotyping of sputum-derived cells
BR112015010220A2 (en) methods of using biomarkers for cancer treatment
EA201591742A1 (en) METHOD FOR IMPROVING DIAGNOSTIC DISEASES USING MEASURED ANALYTES
BR112019006504A2 (en) Avelumab Dosage Regimen For Cancer Treatment
BR112015027249A2 (en) cancer diagnosis method
BR112018007394A2 (en) process for producing an aqueous precipitate of calcium carbonate suspension, aqueous suspension of precipitate calcium carbonate, product, precipitate calcium carbonate, and use of an aqueous precipitate of calcium carbonate
BR112018003779A2 (en) sialyl di-lewis a as expressed in glycoproteins but not glycolipids as a functional cancer target and antibodies to it

Legal Events

Date Code Title Description
B65X Notification of requirement for priority examination of patent application
B65Y Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117)
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B350 Update of information on the portal [chapter 15.35 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]